S3-E11.3 – NAIL-NIT: Challenges of the NAS Score
How can data from NAIL-NIT address the challenges of the NAS score and provide more robust data to diagnose and treat individual patients with the optimal therapy?
February 19, 2022
How can data from NAIL-NIT address the challenges of the NAS score and provide more robust data to diagnose and treat individual patients with the optimal therapy?
How does NAIL-NIT looks to improve on the challenges of histopathology?
NAIL-NIT Study Co-Directors and Steering Committee members from pharmaceutical companies discuss their motivations and why they encourage others to join them
Introducing the NAIL-NIT Consortium: a multi-developer effort to link non-invasive testing (and specific tests) directly to outcomes for Fatty Liver patients
As NASH Prevalence grows, how many patients should we be screening for NAFLD and at what age should we start?
As NAFLD prevalence grows, what can we learn from US and UK data and clinical experience about the value of early NASH diagnosis and education for Fatty Liver patients?
What can the SUNN Study teach us about NASH and NAFLD prevalence in the US today as well as about patient education?
What Can This Recent Study Tell Us About NAFLD and NASH Prevalence in Germany and How To Monitor For It?
What are the implications of the large and growing estimates of NAFLD prevalence on the healthcare system’s ability to screen patients appropriately and route them on the proper treatment pathways?
Jeff Lazarus And Jörn Schattenberg of the Innovations in NAFLD Care 2022 Series join the Surfers to consider innovative elements for a program like this along with the outcomes they would like these programs to produce.
